 | |
- close
- close
|
Business Wire
Jan 28
Comment
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the 12th Annual BIO CEO & Investor Conference being held at the Waldorf=Astoria Hotel in New York City, New York. Harvey J. Berger, M.D., chairman and chief executive
StreetInsider.com
Jan 11
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/Ariad+Pharma+%28ARIA%29+Files+%24125M+Mixed+Shelf/5237269.html for the full story.
Business Wire
Jan 4
Comment
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the 28th Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, California. Harvey J. Berger, M.D., chairman and chief
PR Newswire
Dec 21
Comment
LAS VEGAS, Dec. 21 /PRNewswire-FirstCall/ -- IGT's (NYSE: IGT) sbX(TM) Experience Management System is the ultimate catalyst for change and it's currently installed at ARIA Resort & Casino at CityCenter. Flexibility. Choice. Value. sbX(TM) is the
PR Newswire
Dec 17
Comment
NEW YORK, Dec. 17 /PRNewswire-FirstCall/ -- CKX, Inc. (Nasdaq: CKXE), its subsidiary Elvis Presley Enterprises, Inc. and the remarkable creative team of Cirque du Soleil have unveiled the new Cirque du Soleil show Viva ELVIS for previews at ARIA
Business Wire
Dec 17
Comment
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the completion of patient enrollment in its pivotal, Phase 3 clinical trial of oral ridaforolimus, its investigational mTOR inhibitor, in patients with metastatic soft-tissue and bone
Business Wire
Dec 14
Comment
ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced the presentation of updated clinical data from its Phase 2 study evaluating oral ridaforolimus in combination with trastuzumab (Herceptin®) in patients with resistant, metastatic breast
TheStreet.com
Dec 8
Comment
News and highlights from the American Society of Hematology annual meeting.
Business Wire
Dec 7
Comment
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced positive clinical data from an ongoing Phase 1 study of its investigational, pan-BCR-ABL inhibitor, AP24534, in patients with advanced hematological cancers. The data provide strong clinical
PR Newswire
Dec 1
Comment
LAS VEGAS, Dec. 1 /PRNewswire/ -- CityCenter, Las Vegas unveils five bold new creations from WET, the leading water feature and fountain design firm, based in Los Angeles, CA. WET's designs -- Lumia, Focus, Latisse, Glacia and Halo -- play an
Suggest other news sources for this topic
Thank you for your suggestion
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
ARIA AT A GLANCE
References
| ||||||
|
|
